ArticleJSES international2026
Clinical outcomes of modular segmental megaprosthesis for revision shoulder arthroplasty with severe proximal humerus bone loss at a minimum two year follow-up.
Article in JSES international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Significant proximal humerus bone loss poses a challenge on the outcomes of traditional reverse shoulder arthroplasty implants. Modular Segmental Megaprosthesis (MSM) offers a potential solution to shoulder reconstruction without the need for allograft. However, clinical outcomes of MSM are restricted to case reports and small case series with limited follow-up. Methods: An Institutional Joint Registry Database was used to identify revision shoulder arthroplasty patients using MSM. A retrospective review evaluated implant survivorship, pain relief and functional outcomes at a minimum of 2-year follow-up. Results: Between 2014 and 2022, a total of 28 patients with significant proximal humerus bone loss who underwent revision shoulder arthroplasty reconstruction using MSM were included in this study. At a minimum of 2-year follow-up, the MSM implant survivorship was 85.7% (24 out of 28). Pain level decreased from 7 out of 10 preoperatively to 2 at the 2-year follow-up mark ( Conclusion: The MSM presented a good 2-year survivorship. It demonstrated significant improvement in pain and function in patients with proximal humerus bone loss that underwent arthroplasty revision. These findings support the use of MSM as a salvage procedure in complex shoulder reconstructions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.